Company Encyclopedia
View More
name
Tempest Therapeutics
TPST.US
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd.
1.875 T
TPST.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Pre-market hot trades in US stocks: Nebius up 6.24% in pre-market; Tempest Therapeutics down 5.89% in pre-market

    Nebius pre-market up 6.24%; Tempest Therapeutics pre-market down 5.89%; Sonder pre-market up 155.37%; Inspire Veterinary Partners pre-market up 48.71%; PACS pre-market up 38.80%

    Tracking Unusual Activity·
    US
    NBIS
    -10.97%
    US
    TPST
    -22.53%
    Tracking Unusual Activity·
    US
    NBIS
    -10.97%
    US
    TPST
    -22.53%

    Tempest shares are trading lower after the company announced it has signed agreements to acquire Factor Bioscience's Dual-CAR T programs in an all-stock transaction.

    benzinga_article·
    US
    TPST
    -22.53%
    benzinga_article·
    US
    TPST
    -22.53%

    Tempest Therapeutics Announces New Leadership and Acquisition

    Tempest Therapeutics announced an Asset Purchase Agreement with Erigen LLC and Factor Bioscience Inc. for CAR T-cell therapies, expected to close in early 2026. Dr. Matt Angel will become CEO and President. The deal involves shares and warrants, pending stockholder approval. Analysts rate TPST stock as Hold with a $9.00 target, but TipRanks’ AI Analyst views it as Underperform due to financial challenges and bearish technical analysis. The stock is high risk with potential high reward.

    Tip Ranks·
    US
    TPST
    -22.53%
    Tip Ranks·
    US
    TPST
    -22.53%

    Tempest Therapeutics to Acquire Factor Bioscience Dual-CAR T Programs in All-Stock Deal

    Tempest Therapeutics, Inc. is set to acquire dual-CAR T programs from Factor Bioscience in an all-stock deal, adding TPST-2003 to its pipeline. The transaction, pending stockholder approval, is expected to close in early 2026. Post-acquisition, Matt Angel will become President and CEO, and Stephen Brady will be Chairman. The deal includes an investment commitment from Factor to support operations through mid-2027.

    Reuters·
    US
    TPST
    -22.53%
    Reuters·
    US
    TPST
    -22.53%

    Tempest Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    TPST
    -22.53%
    LB filings·
    US
    TPST
    -22.53%